Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Lycium barbarum bark extract is a botanical extract derived from the bark of the Lycium barbarum plant, also known as goji or wolfberry. While most research and clinical use have focused on the berries, extracts from other plant parts including bark are believed to contain similar bioactive compounds, such as polysaccharides, flavonoids, and carotenoids, that exhibit antioxidant, immune-modulating, anti-inflammatory, and potential neuroprotective and metabolic effects. The extract is indicated primarily as a dietary supplement or functional food, with traditional uses in Chinese medicine for supporting vision, metabolic health, immune regulation, and liver and kidney function. Mechanistically, its effects are attributed to free radical scavenging, modulation of inflammatory signaling, immune activity enhancement, and potential protection against retinal cell apoptosis. Modern human clinical trials have primarily involved berry extracts, but bark extract is presumed to have overlapping pharmacological actions due to similar composition.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on lycium barbarum bark extract.